Baseline characteristics of participants with a history of prior SARS-CoV-2 infection, who received uninterrupted biological therapy since recruitment and had an antibody test between 14 and 70 days after a third dose with an mRNA-based SARS-CoV-2 vaccine
| Variable | Level | Vedolizumab | Infliximab | P value |
| Vaccine | BNT162b2 | 36.2% (67/185) | 41.2% (211/512) | 0.26 |
| ChAdOx1 nCoV-19 | 63.8% (118/185) | 58.8% (301/512) | ||
| Max anti-N prefirst dose | 0.3 (9.6) | 0.2 (3.4) | <0.0001 | |
| Max anti-S prefirst dose | 1.6 (13.0) | 0.6 (3.8) | 0.00022 | |
| Max anti-N presecond dose | 0.7 (14.5) | 0.2 (3.9) | <0.0001 | |
| Max anti-N presampling postsecond dose | 4.2 (12.2) | 1.0 (7.5) | <0.0001 | |
| Max anti-N pre/at sampling postsecond dose ≥0.12 | 97.3% (180/185) | 95.3% (488/512) | 0.29 | |
| Positive PCR or patient-reported swab presampling postsecond dose | 46.5% (86/185) | 53.1% (272/512) | 0.12 | |
| Age (years) | 45.3 (35.9–58.4) | 39.9 (30.3–51.5) | <0.0001 | |
| Sex | Female | 45.4% (84/185) | 42.0% (214/510) | 0.56 |
| Male | 54.9% (101/185) | 57.8% (295/510) | ||
| Intersex | N<5 | N<5 | ||
| Prefer not to say | N<5 | N<5 | ||
| Ethnicity | White | 92.4% (171/185) | 89.8% (458/510) | 0.58 |
| Asian | 4.9% (9/185) | 6.7% (34/510) | ||
| Mixed | N<5 | 1.4% (7/510) | ||
| Black | N<5 | 1.6% (8/510) | ||
| Other | N<5 | N<5 | ||
| Diagnosis | Crohn’s disease | 35.1% (65/185) | 64.8% (332/512) | <0.0001 |
| UC/IBDU | 64.9% (120/185) | 35.2% (180/512) | ||
| Duration of IBD (years) | 10.0 (5.0–17.0) | 9.0 (3.0–16.0) | 0.059 | |
| Age at IBD diagnosis (years) | 33.3 (23.8–41.8) | 27.2 (20.1–37.6) | 0.00010 | |
| Immunomodulators at vaccine | 20.0% (37/185) | 59.4% (304/512) | <0.0001 | |
| 5-ASA | 34.6% (64/185) | 21.3% (109/512) | 0.00049 | |
| Steroids | 5.4% (10/185) | 1.2% (6/512) | 0.0024 | |
| BMI | 26.7 (23.9–31.9) | 26.0 (23.4–29.6) | 0.028 | |
| Heart disease | 4.9% (9/185) | 1.6% (8/509) | 0.023 | |
| Diabetes | 5.9% (11/185) | 2.9% (15/510) | 0.073 | |
| Lung disease | 18.4% (34/185) | 12.5% (64/510) | 0.064 | |
| Kidney disease | 3.8% (7/185) | N<5 | 0.0019 | |
| Cancer | N<5 | N<5 | ||
| Smoker | Yes | 6.5% (12/185) | 6.5% (33/510) | 0.0075 |
| Not currently | 40.0% (74/185) | 27.8% (142/510) | ||
| Never | 53.5% (99/185) | 65.7% (335/510) | ||
| Exposure to documented cases of COVID-19 | 17.3% (32/185) | 13.8% (70/510) | 0.27 | |
| Income deprivation score | 0.107 (0.061–0.164) | 0.091 (0.053–0.164) | 0.085 | |
| Active disease (PRO2) | 17.3% (31/179) | 18.2% (88/484) | 0.91 | |
| Time between first two vaccine doses (weeks) | 10.9 (9.7–11.1) | 10.9 (9.9–11.1) | 0.93 | |
| Time between second and third vaccine doses (weeks) | 27.1 (25.6–29.1) | 27.6 (25.7–30.0) | 0.14 | |
| Time from second dose to serum sample (weeks) | 33.1 (30.1–35.9) | 33.4 (30.3–36.5) | 0.36 | |
| Time from third dose to serum sample (weeks) | 6.1 (3.7–7.6) | 5.7 (3.9–7.7) | 0.96 | |
Values presented are median (IQR) or percentage (numerator/denominator). P values represent the results of a Mann-Whitney U test, Kruskal-Wallis test or Fisher’s exact test.
5-ASA, 5-aminosalicylic acid; BMI, body mass index; IBDU, IBD unclassified; mRNA, messenger RNA; PRO2, IBD disease activity.